Irinotecan in combination with thalidomide in patients with advanced solid tumors: A clinical study with pharmacodynamic and pharmacokinetic evaluation

Cancer Chemotherapy and Pharmacology

Volumn 58, Issue 5, 2006, Pages 585-593

  Allegrini, Giacomo ^a   Di Paolo, Antonello ^b   Cerri, Elisa ^a   Cupini, Samanta ^c   Amatori, Federica ^b   Masi, Gianluca ^a   Danesi, Romano ^b   Marcucci, Lorenzo ^a   Bocci, Guido ^b   Del Tacca, Mario ^b   Falcone, Alfredo ^a,b  

^a Presidio Ospedaliero   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c F Lotti Hospital Pontedera   (Italy)

Author keywords

Diarrhea; Irinotecan; Metastatic disease; Pharmacokinetics; Thalidomide

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN GLUCURONIDE; ANTINEOPLASTIC AGENT; ATROPINE; DEXAMETHASONE; IRINOTECAN; LOPERAMIDE; ONDANSETRON; THALIDOMIDE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CHOLINERGIC SYNDROME; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG FEVER; DRUG INDUCED DISEASE; DRUG METABOLISM; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; MALE; MONOTHERAPY; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; PRIORITY JOURNAL; RISK REDUCTION; SOLID TUMOR; SOMNOLENCE; STOMATITIS; THROMBOCYTOPENIA; VERTIGO; VOMITING; XEROSTOMIA;

ADMINISTRATION, ORAL; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; BRAIN NEOPLASMS; CAMPTOTHECIN; DIARRHEA; DISORDERS OF EXCESSIVE SOMNOLENCE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; THALIDOMIDE; TREATMENT OUTCOME;

EID: 33746687818     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-006-0205-x     Document Type: Article

References (52)

1. Kunimoto T, Nitta K, Kanaka T, Uehara N, Baba H, Takeuchi M, Yokokura T, Sawada S, Miyasaka T, Mutai M (1987) Antitumor activity of 7-ethyl-10 (4-(1-piperidino)-1 piperidino)-1-carboniloxi-campthotecin, a novel water soluble derivative of campthotecin, against murine tumor. Cancer Res 47:5944-5947
2. Canal P, Gay C, Dazeuse A, Douillard JY, Bugat R, Brunet R, Adenis A, Herait P, Lokiec F, Mathieu-Boue A (1996) Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. J Clin Oncol 14:2688-2695
3. Fuchs CS, Moore MR, Harker G, Villa L, Rinaldi D, Hecht JR (2003) Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 21:807-814
4. Negoro S, Masuda N, Takada Y, Sugiura T, Kudoh S, Katakami N, Ariyoshi Y, Ohashi Y, Niitani H, Fukuoka M; CPT-11 Lung Cancer Study Group West (2003) Randomized phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. Br J Cancer 88:335-341
5. Friedman HS, Petros WP, Friedman AH, Schaaf LJ, Kerby T, Lawyer J, Parry M, Houghton PJ, Lovell S, Rasheed K, Cloughsey T, Stewart ES, Colvin OM, Provenzale JM, McLendon RE, Bigner DD, Cokgor I, Haglund M, Rich J, Ashley D, Malczyn J, Elfring GL, Miller LL (1999) Irinotecan therapy in adults with recurrent or progressiv malignant glioma. J Clin Oncol 17:1516-1525
6. Perez EA, Hillman DW, Mailliard JA, Ingle JN, Ryan JM, Fitch TR, Rowland KM, Kardinal CG, Krook JE, Kugler JW, Dakhil SR (2004) Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both. J Clin Oncol 22:2849-2855
7. Kohene CH, Catane R, Klein B, Ducreux M, Thuss-Patience P, Niederle N, Gips M, Preusser P, Knuth A, Clemens M, Bugat R, Figer I, Shani A, Fages B, Di Betta D, Jacques C, Wilke HJ (2003) Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicenter trial. Br J Cancer 89:997-1001
8. Pitot HC, Wender DB, O'Connell MJ, Schroeder G, Goldberg RM, Rubin J,Mailliard JA, Knost JA, Ghosh C, Kirschling RJ,Levitt R, Windschitl HE (1997) Phase II trial of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 15:2910-2919
9. Rougier P, Bugat R, Douillard JY, Culine S, Suc E, Brunet P, Becouarn Y, Ychou M, Marty M, Extra JM, Bonneterre J, Adenis A, Seitz JF, Ganem G, Namer M, Conroy T, Negrier S, Merrouche Y, Burki F, Mousseau M, Herait P, Mahjoubi M (1997) Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-näve patients and patients pretreated with fluorouracil based chemotherapy. J Clin Oncol 15:251-260
10. Cunningham D, Glimelius B (1999) A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. Sem Oncol 26(suppl 5):6-10
11. Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, Navarro M, Morant R, Bleiberg H, Wils J, Awad L, Herait P, Jacques C (1998) Randomized trial of irinotecan versus fluorouracil by continous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352:1407-1412
12. Graeven U, Ridwelski K, Manns M (2000) Irinotecan with bolus 5-fluorouracil and folinic acid in patients with previously untreated metastatic colorectal cancer: an active and safe regiment. Proc Am Soc Clin Oncol 19 abstract no. 952
13. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 355:1041-1047
14. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343:905-914
15. Saltz LB, Niedzwiecki D, Hollis D (2004) Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803). Proc Am Soc Clin Oncol 22: abstract no. 3500
16. Sasaki K, Takasaka H, Kiriyama K (2004) Adjuvant postoperative chemotherapy for Dukes C colorectal cancer; weekly low-dose Irinotecan (CPT-11) plus 5 FU versus oral 5FU only. Proc Am Soc Clin Oncol 22: abstract no. 3735
17. Canal P, Gay C, Dezeuse A, Douillard JY, Bugat R, Brunet R, Adenis A, Herait P, Lokiec F, Mathieu-Boue A (1996) Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. J Clin Oncol 10:2688-2695
18. De Forni M, Bugat R, Chabot GG, Culine S, Extra JM, Gouyette A, Madelaine I, Marty ME, Mathieu-Boue A (1994) Phase I and pharmacokinetics study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res 54:4347-4354
19. Abigerges D, Chabot GG, Armand J, Herait P, Gouyette A, Gandia D (1995) Phase I and pharmacologic studies of the camptothecin analogue irinotecan administered every 3 weeks in cancer ptients. J Clin Oncol 13:210-221
20. Catimel G, Chabot GG, Guastella JP, Dumortier A, Cote C, Engel C, Gouyette A, Mathieu-Boue A, Mahjoubi M, Clavel M (1995) Phase I and pharmacokinetics study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advances solid tumors. Ann Oncol 6:133-140
21. Bleiberg H, Cvitkovic E (1996) Characterisation and clinical management of CPT-11 induced adverse events: the european perspective. Eur J Cancer 32A(suppl 3):S18-S23
22. Conti JA, Kemeny NE, Saltz LB, Huang Y, Tong WP, Chou TC, Sun M, Pulliam S, Gonzalez C (1996) Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 14:709-715
23. Abigerges D, Armand JP, Chabot GC, Da Costa L, Fadel E, Cote C, Herait P, Gandia D (1994) Irinotecan high-dose escalation using intensive high-dose loperamide to control diarrhea. J Nat Cancer Inst 86:446-449
24. Stephens TD, Bunde CJ, Fillemore BJ (2000) Mechanism of action in thalidomide teratogenesis. Biochem Pharmacol 59:1489-1499
25. McHugh SM, Rifkin IR, Deighton J, Wilson AB, Lachmann PJ, Lockwood CM, Ewan PW ( (1995) The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol 99:160-167
26. Kenyon BM, Browne F, D'Amato RJ (1997) Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 64:971-978
27. Or R, Feferman R, Shoshan S (1998) Thalidomide reduces vascular density in granulation tissue of subcutaneously implanted polyvinyl alcohol sponges in guinea pigs. Exp Hematol 26:217-221
28. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565-1571
29. Rajkumar SV, Fonseca R, Dispenzieri A, et al (1999) Thalidomide in the treatment of relapsed and refractory myeloma. Blood 94(suppl 1):316a
30. Fine HA, FiggW D, Jaeckle K, Wen PY, Kyritsis AP, Loeffler JS, Levin VA, Black PM, Kaplan R, Pluda JM, Yung WK (2000) A phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 18:708-715
31. Figg WD, Dahut W, Duray P, Hamilton M, Tompkins A, Steinberg SM, Jones E, Premkumar A, Linehan WM, Floeter MK, Chen CC, Dixon S, Kohler DR, Kruger EA, Gubish E, Pluda JM, Reed E (2001) A Randomized phase II trial of docetaxel (taxotere) plus thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res 7:1888-1893
32. Motzer RJ, Berg W, Ginsberg M, Russo P, Vuky J, Yu R, Bacik J, Mazumdar M (2002) Phase II trial of Thalidomide for patients with advanced renal cell carcinoma. J Clin Oncol 20:302-306
33. Govindarajan R, Heaton KM, Broadwater R, Zeitlin A, Lang NP, Hauer-Jensen M (2000) Effect of thalidomide on gastrointestinal toxic effects of irinotecan. Lancet 356:566-567
34. Govindarajan R (2000) Irinotecan/thalidomide in metastatic colorectal cancer. Oncology 16(suppl):23-26
35. Govindarajan R, Maddox A, Gray P (2003) Irinotecan and thalidomide prolong disease free and overall survival in 5FU refractory metastatic colorectal cancer. Proc Am Soc Clin Oncol 22:249: abstract no. 997
36. Barileiro I, Gandia D, Armand JP, Mathieu-Boue A, Re M, Gouyette A, Chabot GG (1992) Simultaneus determination of the camptothecin analogue CPT-11 and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetics studies in cancer patients. J Chromatogr Biomed Appl 575:275-280
37. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, National Cancer Institute of United states, National Cancer Institute Of Canada. J Natl Cancer Inst 92:205-216
38. Friedman LM, Furberg DC, De Mets DL. Fundamentals of clinical trials. Third Edition, Springer
39. Crews KR, Stewart CF, Jones-Wallace D, Thompson SJ, Houghton PJ, Heideman RL, Fouladi M, Bowers DC, Chintagumpala MM, Gajjar A (2002) Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy. Clin Cancer Res 8:2202-2209
40. Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE, Ratain MJ (1994) Metabolic fate of irinotecan in humans: correlation of glicuronation with diarrhea. Cancer Res 54:3723-3725
41. Gupta E, Mick R, Ramirez J, Wang X, Lestingi TM, Vokes EE, Ratain MJ (1997) Pharmacokinetic and pharmacodinamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. J Clin Oncol 15:1502-1510
42. Mick R, Gupta E, Vokes EE, Ratain MJ (1996) Limited sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity. J Clin Oncol 14:2012-2019
43. Haaz MC, Rivory LP, Riche C, Robert J (1997) The transformation of irinotecan (CPT-11) to its active metabolite SN-38 by human liver microsomes. Differential hydrolysis for the lactone and carboxylate forms. Naunyn Schmiedebergs Arch Pharmacol 356:257-262
44. Charasson V, Haaz MC, Robert J (2002) Determination of drug interactions occurring with the metabolic pathways of irinotecan. Drug Metab Dispos 30:731-733
45. Haaz MC, Riche C, Rivory LP, Robert J (1998) Biosynthesis of an aminopiperidino metabolite of irinotecan [7-ethyl-10-[4-(1-piperidino)-1- piperidino]carbonyloxycamptothecine] by human hepatic microsomes. Drug Metab Dispos 26:769-774
46. Ando Y, Fuse E, Figg WD (2002) Thalidomide metabolism by the CYP2C subfamily. Clin Cancer Res 8:1964-1973
47. Lu J, Palmer BD, Kestell P, Browett P, Baguley BC, Muller G, Ching LM (2003) Thalidomide metabolites in mice and patients with multiple myeloma. Clin Cancer Res 9:1680-1688
48. Teo SK, Sabourin PJ, O'Brien K, Kook KA, Thomas SD (2000) Metabolism of thalidomide in human microsomes, cloned human Cytochrome P-450 isoenzymes, and Hansen's disease patients. J Biochem Mol Toxicol 14:140-147
49. Lu J, Helsby N, Palmer BD, Tingle M, Baguley BC, Kestell P, Ching LM (2004) Metabolism of thalidomide in liver microsomes of mice, rabbits, and humans. J Pharmacol Exp Ther 310:571-577
50. Patel NJ, Zamek-Gliszczynski MJ, Zhang P, Han YH, Jansen PL, Meier PJ, Stieger B, Brouwer KL (2003) Phenobarbital alters hepatic Mrp2 function by direct and indirect interactions. Mol Pharmacol 64:154-159
51. Weiss J, Kerpen CJ, Lindenmaier H, Dormann SM, Haefeli WE (2003) Interaction of antiepileptic drugs with human P-glycoprotein in vitro. J Pharmacol Exp Ther 307:262-267
52. Xiong H, Suzuki H, Sugiyama Y, Meier PJ, Pollack GM, Brouwer KL (2002) Mechanisms of impaired biliary excretion of acetaminophen glucuronide after acute phenobarbital treatment or phenobarbital pretreatment. Drug Metab Dispos 30:962-969